J. B. Domachowske and H. F. Rosenberg, Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment, Clin Microbiol Rev, vol.12, pp.298-309, 1999.
DOI : 10.1128/cmr.12.2.298
URL : https://cmr.asm.org/content/cmr/12/2/298.full.pdf

P. L. Collins and B. S. Graham, Viral and host factors in human respiratory syncytial virus pathogenesis, J Virol, vol.82, pp.2040-55, 2008.

A. Mejias, S. Chavez-bueno, H. S. Jafri, and O. Ramilo, Respiratory syncytial virus infections: old challenges and new opportunities, Pediatr Infect Dis J, vol.24, pp.196-203, 2005.

H. Nair, D. J. Nokes, B. D. Gessner, M. Dherani, S. A. Madhi et al., Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis, Lancet, vol.375, pp.1545-55, 2010.

S. Van-drunen-littel-van-den-hurk and E. R. Watkiss, Pathogenesis of respiratory syncytial virus, Curr Opin Virol, vol.2, pp.300-305, 2012.

L. Navas, E. Wang, V. De-carvalho, and J. Robinson, Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada, J Pediatr, vol.121, pp.348-54, 1992.

E. E. Wang, B. J. Law, F. D. Boucher, D. Stephens, J. L. Robinson et al., Pediatric Investigators Collaborative Network on Infections in Canada (PIC-NIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection, J Pediatr, vol.129, pp.390-395, 1996.

F. D. Martinez, Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma, Pediatr Infect Dis J, vol.22, pp.76-82, 2003.

L. L. Sweetman, Y. T. Ng, I. J. Butler, and J. B. Bodensteiner, Neurologic complications associated with respiratory syncytial virus, Pediatr Neurol, vol.32, pp.307-317, 2005.

M. Eisenhut, Extrapulmonary manifestations of severe respiratory syncytial virus infection -a systematic review, Crit Care, vol.10, p.107, 2006.

M. Eisenhut, Cerebral involvement in respiratory syncytial virus disease, Brain Dev, vol.29, p.454, 2007.
DOI : 10.1016/j.braindev.2006.11.007

S. Morichi, H. Kawashima, H. Ioi, G. Yamanaka, Y. Kashiwagi et al., Classification of acute encephalopathy in respiratory syncytial virus infection, J Infect Chemother, vol.17, pp.776-81, 2011.

J. A. Espinoza, K. Bohmwald, P. F. Cespedes, R. S. Gomez, S. A. Riquelme et al., Impaired learning resulting from respiratory syncytial virus infection, Proc Natl Acad Sci U S A, vol.110, pp.9112-9119, 2013.
DOI : 10.1073/pnas.1217508110
URL : http://europepmc.org/articles/pmc3670318?pdf=render

N. Aaopcoidacofa, Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV, Pediatrics, vol.102, pp.1211-1217, 1998.

S. Johnson, C. Oliver, G. A. Prince, V. G. Hemming, D. S. Pfarr et al., Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus, J Infect Dis, vol.176, pp.1215-1239, 1997.

T. Group and . Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants, Pediatrics, vol.102, pp.531-538, 1998.

A. Mejias, S. Chavez-bueno, A. M. Rios, J. Saavedra-lozano, M. Fonseca-aten et al., Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model, Antimicrob Agents Chemother, vol.48, pp.1811-1833, 2004.

C. Harkensee, M. Brodlie, N. D. Embleton, and M. Mckean, Passive immunisation of preterm infants with palivizumab against RSV infection, J Infect, vol.52, pp.2-8, 2006.

N. D. Embleton, C. Harkensee, and M. C. Mckean, Palivizumab for preterm infants. Is it worth it?, Arch Dis Child Fetal Neonatal Ed, vol.90, pp.286-295, 2005.

H. W. Kim, J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock et al., Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine, Am J Epidemiol, vol.89, pp.422-456, 1969.

R. C. Welliver, T. N. Kaul, M. Sun, and P. L. Ogra, Defective regulation of immune responses in respiratory syncytial virus infection, J Immunol, vol.133, pp.1925-1955, 1984.

R. C. Welliver, D. T. Wong, M. Sun, E. Middleton, R. S. Vaughan et al., The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection, N Engl J Med, vol.305, pp.841-847, 1981.

G. A. Prince, J. P. Prieels, M. Slaoui, and D. D. Porter, Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus), Lab Invest, vol.79, pp.1385-92, 1999.

G. A. Prince, S. J. Curtis, K. C. Yim, and D. D. Porter, Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine, J Gen Virol, vol.82, pp.2881-2889, 2001.

F. P. Polack, M. N. Teng, P. L. Collins, G. A. Prince, M. Exner et al., A role for immune complexes in enhanced respiratory syncytial virus disease, J Exp Med, vol.196, pp.859-65, 2002.

S. M. Bueno, P. A. Gonzalez, R. Pacheco, E. D. Leiva, K. M. Cautivo et al., Host immunity during RSV pathogenesis, Int Immunopharmacol, vol.8, pp.1320-1329, 2008.
DOI : 10.1016/j.intimp.2008.03.012

R. E. Blount, J. A. Morris, and R. E. Savage, Recovery of cytopathogenic agent from chimpanzees with coryza, Proc Soc Exp Biol Med, vol.92, pp.544-553, 1956.

R. Chanock and L. Finberg, Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children, Am J Hyg, vol.66, pp.291-300, 1957.

R. Chanock, B. Roizman, and R. Myers, Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization, Am J Hyg, vol.66, pp.281-90, 1957.

A. Chang and R. E. Dutch, Paramyxovirus fusion and entry: multiple paths to a common end, Viruses, vol.4, pp.613-649, 2012.
DOI : 10.3390/v4040613
URL : http://www.mdpi.com/1999-4915/4/4/613/pdf

P. S. Gould and A. J. Easton, Coupled translation of the second open reading frame of M2 mRNA is sequence dependent and differs significantly within the subfamily Pneumovirinae, J Virol, vol.81, pp.8488-96, 2007.

D. Hacking and J. Hull, Respiratory syncytial virus -viral biology and the host response, J Infect, vol.45, pp.18-24, 2002.
DOI : 10.1053/jinf.2002.1015

V. M. Cowton, D. R. Mcgivern, and R. Fearns, Unravelling the complexities of respiratory syncytial virus RNA synthesis, J Gen Virol, vol.87, pp.1805-1826, 2006.

P. L. Ogra, Respiratory syncytial virus: the virus, the disease and the immune response, Paediatr Respir Rev, vol.5, pp.119-145, 2004.

P. L. Collins and J. A. Melero, Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years, Virus Res, vol.162, pp.80-99, 2011.
DOI : 10.1016/j.virusres.2011.09.020
URL : http://europepmc.org/articles/pmc3221877?pdf=render

S. W. Gan, L. Ng, X. Lin, X. Gong, and J. Torres, Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain, Protein Sci, vol.17, pp.813-833, 2008.

M. Batonick and G. W. Wertz, Requirements for human respiratory syncytial virus glycoproteins in assembly and egress from infected cells, Adv Virol, 2011.

L. Liljeroos, M. A. Krzyzaniak, A. Helenius, and S. J. Butcher, Architecture of respiratory syncytial virus revealed by electron cryotomography, Proc Natl Acad Sci U S A, vol.110, pp.11133-11141, 2013.

E. Pretel, G. Camporeale, and G. De-prat-gay, The non-structural NS1 protein unique to respiratory syncytial virus: a two-state folding monomer in quasiequilibrium with a stable spherical oligomer, PLOS ONE, vol.8, p.74338, 2013.

M. N. Teng, S. S. Whitehead, and P. L. Collins, Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo, Virology, vol.289, pp.283-96, 2001.

C. B. Hall, D. Jr, R. G. Schnabel, K. C. Geiman, and J. M. , Infectivity of respiratory syncytial virus by various routes of inoculation, Infect Immun, vol.33, pp.779-83, 1981.

M. T. Lotz and R. S. Peebles, Mechanisms of respiratory syncytial virus modulation of airway immune responses, Curr Allergy Asthma Rep, vol.12, pp.380-387, 2012.

P. Mastrangelo and R. G. Hegele, RSV fusion: time for a new model, Viruses, vol.5, pp.873-85, 2013.

F. Tayyari, D. Marchant, T. J. Moraes, W. Duan, P. Mastrangelo et al., Identification of nucleolin as a cellular receptor for human respiratory syncytial virus, Nat Med, vol.17, pp.1132-1137, 2011.

M. K. Lay, P. A. Gonzalez, M. A. Leon, P. F. Cespedes, S. M. Bueno et al., Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response, Microbes Infect, vol.15, pp.230-272, 2013.

C. B. Hall, E. A. Simoes, and L. J. Anderson, Clinical and epidemiologic features of respiratory syncytial virus, Curr Top Microbiol Immunol, vol.372, pp.39-57, 2013.
DOI : 10.1007/978-3-642-38919-1_2

W. Sr and R. C. , The immune response to respiratory syncytial virus infection: friend or foe, Clin Rev Allergy Immunol, vol.34, pp.163-73, 2008.

D. Roymans and A. Koul, Treatment of respiratory syncytial virus infection: past, present and future, Tech, p.39, 2011.
DOI : 10.5772/26528
URL : https://www.intechopen.com/chapter/pdf-download/24399

M. L. Houben, F. E. Coenjaerts, J. W. Rossen, M. E. Belderbos, R. W. Hofland et al., Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community, J Med Virol, vol.82, pp.1266-71, 2010.

H. W. Kim, S. L. Leikin, J. Arrobio, C. D. Brandt, R. M. Chanock et al., Cellmediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection, Pediatr Res, vol.10, pp.75-83, 1976.
DOI : 10.1203/00006450-197601000-00015

R. Scott, A. Kaul, M. Scott, Y. Chiba, and P. L. Ogra, Development of in vitro correlates of cell-mediated immunity to respiratory syncytial virus infection in humans, J Infect Dis, vol.137, pp.810-817, 1978.

C. L. Siezen, L. Bont, H. M. Hodemaekers, M. J. Ermers, G. Doornbos et al., Genetic susceptibility to respiratory syncytial virus bronchiolitis in preterm children is associated with airway remodeling genes and innate immune genes, Pediatr Infect Dis J, vol.28, pp.333-338, 2009.

E. A. Simoes, Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease, J Pediatr, vol.143, pp.118-144, 2003.
DOI : 10.1067/s0022-3476(03)00511-0

W. Gut, K. Pancer, E. Abramczuk, A. Czescik, M. Dunal-szczepaniak et al., RSV respiratory infection in children under 5 y.o.-dynamics of the immune response Th1/Th2 and IgE, Przegl Epidemiol, vol.67, pp.105-114, 2013.

H. C. Lee, M. B. Headley, Y. M. Loo, A. Berlin, G. Jr et al., Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection, J Allergy Clin Immunol, vol.130, pp.1187-96, 1185.

Y. Becker, Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy -a review, Virus Genes, vol.33, pp.235-52, 2006.

N. Sigurs, R. Bjarnason, F. Sigurbergsson, and B. Kjellman, Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7, Am J Respir Crit Care Med, vol.161, pp.1501-1508, 2000.

N. Krishnamoorthy, A. Khare, T. B. Oriss, M. Raundhal, C. Morse et al., Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma, Nat Med, vol.18, pp.1525-1555, 2012.

E. Whimbey, R. B. Couch, J. A. Englund, M. Andreeff, J. M. Goodrich et al., Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia, Clin Infect Dis, vol.21, pp.376-385, 1995.

J. P. Torres, A. M. Gomez, S. Khokhar, V. G. Bhoj, C. Tagliabue et al., Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice, Respir Res, vol.11, p.125, 2010.

J. J. Millichap and M. S. Wainwright, Neurological complications of respiratory syncytial virus infection: case series and review of literature, J Child Neurol, vol.24, pp.1499-503, 2009.

S. M. Bueno, P. A. Gonzalez, C. A. Riedel, L. J. Carreno, A. E. Vasquez et al., Local cytokine response upon respiratory syncytial virus infection, Immunol Lett, vol.136, pp.122-131, 2011.
DOI : 10.1016/j.imlet.2010.12.003

J. F. Bermejo-martin, G. Mc, D. Lejarazu, R. O. Ardura, J. Eiros et al., Predominance of Th2 cytokines, CXC chemokines and innate immunity mediators at the mucosal level during severe respiratory syncytial virus infection in children, Eur Cytokine Netw, vol.18, pp.162-169, 2007.

F. J. Culley, A. M. Pennycook, J. S. Tregoning, J. S. Dodd, G. Walzl et al., Role of CCL5 (RANTES) in viral lung disease, J Virol, vol.80, pp.8151-8158, 2006.

R. P. Garofalo, J. Patti, K. A. Hintz, V. Hill, P. L. Ogra et al., Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis, J Infect Dis, vol.184, pp.393-402, 2001.

C. M. Oshansky, J. P. Barber, J. Crabtree, and R. A. Tripp, Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells, J Infect Dis, vol.201, pp.1201-1208, 2010.

H. F. Rosenberg and J. B. Domachowske, Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics, Curr Med Chem, vol.19, pp.1424-1455, 2012.

R. A. Tripp, C. Oshansky, and R. Alvarez, Cytokines and respiratory syncytial virus infection, Proc Am Thorac Soc, vol.2, pp.147-156, 2005.

P. Jaovisidha, M. E. Peeples, A. A. Brees, L. R. Carpenter, and J. N. Moy, Respiratory syncytial virus stimulates neutrophil degranulation and chemokine release, J Immunol, vol.163, pp.2816-2836, 1999.

P. M. De-graaff, E. C. De-jong, T. M. Van-capel, M. E. Van-dijk, P. J. Roholl et al., Respiratory syncytial virus infection of monocyte-derived dendritic cells decreases their capacity to activate CD4T cells, J Immunol, vol.175, pp.5904-5915, 2005.

J. R. Panuska, M. I. Hertz, H. Taraf, A. Villani, and N. M. Cirino, Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients, Am Rev Respir Dis, vol.145, pp.934-943, 1992.

H. Bartz, F. Buning-pfaue, O. Turkel, and U. Schauer, Respiratory syncytial virus induces prostaglandin E2, IL-10 and IL-11 generation in antigen presenting cells, Clin Exp Immunol, vol.129, pp.438-483, 2002.

A. Guerrero-plata, A. Casola, G. Suarez, X. Yu, L. Spetch et al., Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus, Am J Respir Cell Mol Biol, vol.34, pp.320-329, 2006.

P. K. Pribul, J. Harker, B. Wang, H. Wang, J. S. Tregoning et al., Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development, J Virol, vol.82, pp.4441-4449, 2008.

J. L. Reed, Y. A. Brewah, T. Delaney, T. Welliver, T. Burwell et al., Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis, J Infect Dis, vol.198, pp.1783-93, 2008.
DOI : 10.1086/593173
URL : https://academic.oup.com/jid/article-pdf/198/12/1783/18053847/198-12-1783.pdf

K. M. Empey, J. G. Orend, R. S. Peebles, L. Egana, K. A. Norris et al., Stimulation of immature lung macrophages with intranasal interferon gamma in a novel neonatal mouse model of respiratory syncytial virus infection, PLoS ONE, vol.7, p.40499, 2012.

A. Dakhama, T. Z. Vitalis, and R. G. Hegele, Persistence of respiratory syncytial virus (RSV) infection and development of RSV-specific IgG1 response in a guineapig model of acute bronchiolitis, Eur Respir J, vol.10, pp.20-26, 1997.

J. V. Williams, J. H. Weitkamp, D. L. Blum, B. J. Lafleur, C. Jr et al., The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations, Mol Immunol, vol.47, pp.407-421, 2009.

J. Valosky, H. Hishiki, T. E. Zaoutis, and S. E. Coffin, Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus, Clin Diagn Lab Immunol, vol.12, pp.171-180, 2005.

A. Rico, M. Trento, A. Ramos, M. Johnstone, C. et al., Human respiratory syncytial virus infects and induces activation markers in mouse B lymphocytes, Immunol Cell Biol, vol.87, pp.344-50, 2009.

M. A. Rico, S. Infantes, M. Ramos, A. Trento, C. Johnstone et al., TLR4-independent upregulation of activation markers in mouse B lymphocytes infected by HRSV, Mol Immunol, vol.47, pp.1802-1809, 2010.

P. A. Gonzalez, C. E. Prado, E. D. Leiva, L. J. Carreno, S. M. Bueno et al., Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells, Proc Natl Acad Sci U S A, vol.105, pp.14999-5004, 2008.
DOI : 10.1073/pnas.0802555105
URL : http://www.pnas.org/content/105/39/14999.full.pdf

L. E. Yauch, R. M. Zellweger, M. F. Kotturi, A. Qutubuddin, J. Sidney et al., A protective role for dengue virus-specific CD8
DOI : 10.4049/jimmunol.0801974
URL : http://www.jimmunol.org/content/182/8/4865.full.pdf

. +-t-cells, J Immunol, vol.182, pp.4865-73, 2009.

J. Dodd, S. Riffault, J. S. Kodituwakku, A. C. Hayday, and P. J. Openshaw, Pulmonary V gamma 4+ gamma delta T cells have proinflammatory and antiviral effects in viral lung disease, J Immunol, vol.182, pp.1174-81, 2009.

B. Shrestha, T. Ng, H. J. Chu, M. Noll, and M. S. Diamond, The relative contribution of antibody and CD8

, + T cells to vaccine immunity against West Nile encephalitis virus, Vaccine, vol.26, pp.2020-2053, 2008.

D. Kolli, E. L. Bataki, L. Spetch, A. Guerrero-plata, A. M. Jewell et al., T lymphocytes contribute to antiviral immunity and pathogenesis in experimental human metapneumovirus infection, J Virol, vol.82, pp.8560-8569, 2008.

S. Frey, C. D. Krempl, A. Schmitt-graff, and S. Ehl, Role of T cells in virus control and disease after infection with pneumonia virus of mice, J Virol, vol.82, pp.11619-11646, 2008.

Y. Shishkova, H. Harms, G. Krohne, E. Avota, and S. Schneider-schaulies, Immune synapses formed with measles virus-infected dendritic cells are unstable and fail to sustain T cell activation, Cell Microbiol, vol.9, pp.1974-86, 2007.

J. Chang and T. J. Braciale, Respiratory syncytial virus infection suppresses lung CD8 + T-cell effector activity and peripheral CD8 + T-cell memory in the respiratory tract, Nat Med, vol.8, pp.54-60, 2002.

J. Chang, S. Y. Choi, H. T. Jin, Y. C. Sung, and T. J. Braciale, Improved effector activity and memory CD8T cell development by IL-2 expression during experimental respiratory syncytial virus infection, J Immunol, vol.172, pp.503-511, 2004.
DOI : 10.4049/jimmunol.172.1.503
URL : http://www.jimmunol.org/content/172/1/503.full.pdf

S. Vallbracht, H. Unsold, and S. Ehl, Functional impairment of cytotoxic T cells in the lung airways following respiratory virus infections, Eur J Immunol, vol.36, pp.1434-1476, 2006.

M. R. Olson and S. M. Varga, Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus, Expert Rev Vaccines, vol.7, pp.1239-55, 2008.
DOI : 10.1586/14760584.7.8.1239
URL : http://europepmc.org/articles/pmc2630464?pdf=render

S. M. Varga, X. Wang, R. M. Welsh, and T. J. Braciale, Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells, Immunity, vol.15, pp.637-683, 2001.

S. L. Cyr, T. Jones, I. Stoica-popescu, A. Brewer, S. Chabot et al., Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology, Vaccine, vol.25, pp.5378-89, 2007.

R. Zeng, Z. Zhang, X. Mei, W. Gong, and L. Wei, Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-like protein in mice, Biochem Biophys Res Commun, vol.377, pp.495-504, 2008.

A. Bukreyev, I. M. Belyakov, J. A. Berzofsky, B. R. Murphy, and P. L. Collins, Granulocytemacrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells, J Virol, vol.75, pp.12128-12168, 2001.

A. Bukreyev, S. S. Whitehead, C. Prussin, B. R. Murphy, and P. L. Collins, Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines, J Virol, vol.74, pp.7151-7158, 2000.

B. Voges, S. Vallbracht, G. Zimmer, S. Bossow, W. J. Neubert et al., Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies, Cell Immunol, vol.247, pp.85-94, 2007.

S. M. Bueno, P. A. Gonzalez, K. M. Cautivo, J. E. Mora, E. D. Leiva et al., Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG, Proc Natl Acad Sci U S A, vol.105, pp.20822-20829, 2008.

C. B. Hall, E. E. Walsh, C. E. Long, and K. C. Schnabel, Immunity to and frequency of reinfection with respiratory syncytial virus, J Infect Dis, vol.163, pp.693-701, 1991.

W. P. Glezen, L. H. Taber, A. L. Frank, and J. A. Kasel, Risk of primary infection and reinfection with respiratory syncytial virus, Am J Dis Child, vol.140, pp.543-549, 1986.

B. R. Murphy, B. S. Graham, G. A. Prince, E. E. Walsh, R. M. Chanock et al., Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection, J Clin Microbiol, vol.23, pp.1009-1023, 1986.

B. Adkins, C. Leclerc, and S. Marshall-clarke, Neonatal adaptive immunity comes of age, Nat Rev Immunol, vol.4, pp.553-64, 2004.

O. Levy, Innate immunity of the newborn: basic mechanisms and clinical correlates, Nat Rev Immunol, vol.7, pp.379-90, 2007.

T. J. Ruckwardt, K. L. Bonaparte, M. C. Nason, and B. S. Graham, Regulatory T cells promote early influx of CD8

, + T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities, J Virol, vol.83, pp.3019-3047, 2009.

R. B. Fulton, D. K. Meyerholz, and S. M. Varga, Foxp3 + CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8T cell response during respiratory syncytial virus infection, J Immunol, vol.185, pp.2382-92, 2010.

D. C. Lee, J. A. Harker, J. S. Tregoning, S. F. Atabani, C. Johansson et al., CD25 + natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection, J Virol, vol.84, pp.8790-8798, 2010.

J. Loebbermann, H. Thornton, L. Durant, T. Sparwasser, K. E. Webster et al., Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection, Mucosal Immunol, vol.5, pp.161-72, 2012.

L. R. Durant, S. Makris, C. M. Voorburg, J. Loebbermann, C. Johansson et al., Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice, J Virol, vol.87, pp.10946-54, 2013.

S. Raiden, J. Pandolfi, F. Payaslian, M. Anderson, N. Rivarola et al., Depletion of circulating regulatory T cells during severe respiratory syncytial virus infection in young children, Am J Respir Crit Care Med, vol.189, pp.865-873, 2014.

J. Loebbermann, L. Durant, H. Thornton, C. Johansson, and P. J. Openshaw, Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells, Proc Natl Acad Sci U S A, vol.110, pp.2987-92, 2013.

B. J. Law, E. E. Wang, N. Macdonald, J. Mcdonald, S. Dobson et al., Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database, Pediatrics, vol.99, p.7, 1997.

K. Ventre and A. G. Randolph, Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children, Cochrane Database Syst Rev, p.181, 2007.

K. Andries, M. Moeremans, T. Gevers, R. Willebrords, C. Sommen et al., Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus, Antiviral Res, vol.60, pp.209-228, 2003.
DOI : 10.1016/j.antiviral.2003.07.004

J. L. Douglas, M. L. Panis, E. Ho, K. Y. Lin, S. H. Krawczyk et al., Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms, Antimicrob Agents Chemother, vol.49, pp.2460-2466, 2005.
DOI : 10.1128/aac.49.6.2460-2466.2005
URL : https://aac.asm.org/content/49/6/2460.full.pdf

M. C. Dunn, D. A. Knight, and W. J. Waldman, Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide, Antivir Ther, vol.16, pp.309-326, 2011.

W. Olszewska, G. Ispas, C. Schnoeller, D. Sawant, T. Van-de-casteele et al., Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model, Eur Respir J, vol.38, pp.401-409, 2011.

V. Razinkov, A. Gazumyan, A. Nikitenko, G. Ellestad, and G. Krishnamurthy, RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein, Chem Biol, vol.8, pp.645-59, 2001.

Z. Sun, Y. Pan, S. Jiang, and L. Lu, Respiratory syncytial virus entry inhibitors targeting the F protein, Viruses, vol.5, pp.211-236, 2013.

W. T. Friedewald, B. R. Forsyth, C. B. Smith, M. A. Gharpure, and R. M. Chanock, Low-temperature-grown RS virus in adult volunteers, JAMA, vol.204, pp.690-694, 1968.

J. H. Schickli, J. Kaur, and R. S. Tang, Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030DeltaSH) at permissive and non-permissive temperatures, Virus Res, vol.169, pp.38-47, 2012.

D. M. Lindell, S. B. Morris, M. P. White, L. E. Kallal, P. K. Lundy et al., A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease, PLoS ONE, vol.6, p.21823, 2011.

B. Schepens, L. I. Ibanez, D. Baets, S. Hultberg, A. Bogaert et al., Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion, J Infect Dis, vol.204, pp.1692-701, 2011.

P. Vanlandschoot, C. Stortelers, E. Beirnaert, L. I. Ibanez, B. Schepens et al., Nanobodies(R): new ammunition to battle viruses, Antiviral Res, vol.92, pp.389-407, 2011.

A. Hultberg, N. J. Temperton, V. Rosseels, M. Koenders, M. Gonzalez-pajuelo et al., Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules, PLoS ONE, vol.6, p.17665, 2011.
DOI : 10.1371/journal.pone.0017665
URL : https://doi.org/10.1371/journal.pone.0017665

A. Rigter, I. Widjaja, H. Versantvoort, F. E. Coenjaerts, M. Van-roosmalen et al., A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles, PLoS ONE, vol.8, p.71072, 2013.

J. K. Kaufmann and D. M. Nettelbeck, Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond, Trends Mol Med, vol.18, pp.365-76, 2012.

Q. L. Matthews, A. Fatima, Y. Tang, B. A. Perry, Y. Tsuruta et al., HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach, PLoS ONE, vol.5, p.11815, 2010.

N. J. Schuldt and A. Amalfitano, Malaria vaccines: focus on adenovirus based vectors, Vaccine, vol.30, pp.5191-5199, 2012.

H. Y. Shao, S. L. Yu, C. Sia, Y. Chen, E. Chitra et al., Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses, Vaccine, vol.27, pp.5460-71, 2009.

A. Krause, Y. Xu, S. Ross, W. Wu, J. Joh et al., Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine, Virol J, vol.8, p.375, 2011.

D. Baets, S. Schepens, B. Sedeyn, K. Schotsaert, M. Roose et al., Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice, J Virol, vol.87, pp.3314-3337, 2013.

F. S. Quan, Y. Kim, S. Lee, H. Yi, S. M. Kang et al., Virus like particle vaccine induces protection against respiratory syncytial virus infection in mice, J Infect Dis, vol.204, pp.987-95, 2011.

R. Garg, L. Latimer, E. Simko, V. Gerdts, A. Potter et al., Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation, J Gen Virol, vol.95, pp.301-307, 2014.

S. Garlapati, R. Garg, R. Brownlie, L. Latimer, E. Simko et al., Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles, Vaccine, vol.30, pp.5206-5220, 2012.

R. Garg, L. Latimer, V. Gerdts, A. Potter, and . Van-drunen, Littel-van den Hurk S. Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity, J Gen Virol, vol.95, pp.1043-54, 2014.

G. Smith, R. Raghunandan, Y. Wu, Y. Liu, M. Massare et al., Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats, PLoS ONE, vol.7, p.50852, 2012.

G. M. Glenn, G. Smith, L. Fries, R. Raghunandan, H. Lu et al., Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine, Vaccine, vol.31, pp.524-556, 2013.

A. Cherukuri, K. L. Stokes, K. Patton, H. Kuo, K. Sakamoto et al., An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice, Immun Ageing, vol.9, p.21, 2012.

E. A. Henderson, D. G. Alber, R. C. Baxter, S. K. Bithell, J. Budworth et al., 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate, J Med Chem, vol.50, pp.1685-92, 2007.

J. Chapman, E. Abbott, D. G. Alber, R. C. Baxter, S. K. Bithell et al., RSV604, a novel inhibitor of respiratory syncytial virus replication, Antimicrob Agents Chemother, vol.51, pp.3346-53, 2007.

S. Barik, Treating respiratory viral diseases with chemically modified, second generation intranasal siRNAs, Methods Mol Biol, vol.487, pp.331-372, 2009.

W. Zhang and R. A. Tripp, RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response, J Virol, vol.82, pp.12221-12252, 2008.

V. Bitko, A. Musiyenko, O. Shulyayeva, and S. Barik, Inhibition of respiratory viruses by nasally administered siRNA, Nat Med, vol.11, pp.50-55, 2005.

J. Devincenzo, R. Lambkin-williams, T. Wilkinson, J. Cehelsky, S. Nochur et al., A randomized, double-blind, placebo-controlled study of an RNAibased therapy directed against respiratory syncytial virus, Proc Natl Acad Sci U S A, vol.107, pp.8800-8805, 2010.

G. J. Fennelly, J. L. Flynn, V. Ter-meulen, U. G. Liebert, and B. R. Bloom, Recombinant bacille Calmette-Guerin priming against measles, J Infect Dis, vol.172, pp.698-705, 1995.
DOI : 10.1093/infdis/172.3.698

M. Dennehy, W. Bourn, D. Steele, and A. L. Williamson, Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine, Vaccine, vol.25, pp.3646-57, 2007.

K. M. Cautivo, S. M. Bueno, C. M. Cortes, A. Wozniak, C. A. Riedel et al., Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guerin promotes virus clearance and protects from infection, J Immunol, vol.185, pp.7633-7678, 2010.

M. N. Widjojoatmodjo, J. Boes, M. Van-bers, Y. Van-remmerden, and P. J. Roholl, Luytjes W. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats, Virol J, vol.7, p.114, 2010.

L. M. Haynes, H. Caidi, G. U. Radu, C. Miao, J. L. Harcourt et al., Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice, J Infect Dis, vol.200, pp.439-486, 2009.

P. A. Jorquera, Y. Choi, K. E. Oakley, T. J. Powell, J. G. Boyd et al., Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease, PLOS ONE, vol.8, p.74905, 2013.

G. U. Rey, C. Miao, H. Caidi, S. U. Trivedi, J. L. Harcourt et al., Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice, PLOS ONE, vol.8, p.83075, 2013.

S. Lee, K. L. Stokes, M. G. Currier, K. Sakamoto, N. W. Lukacs et al., , p.8

, + T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice, J Virol, vol.86, pp.13016-13040, 2012.

P. F. Wright, R. A. Karron, R. B. Belshe, J. Thompson, C. Jr et al., Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy, J Infect Dis, vol.182, pp.1331-1373, 2000.

R. A. Karron, P. F. Wright, R. B. Belshe, B. Thumar, R. Casey et al., Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants, J Infect Dis, vol.191, pp.1093-104, 2005.

C. Luongo, C. C. Winter, P. L. Collins, and U. J. Buchholz, Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature, J Virol, vol.87, pp.1985-96, 2013.

T. Kamphuis, M. Shafique, T. Meijerhof, T. Stegmann, J. Wilschut et al., Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats, Vaccine, vol.31, pp.2169-76, 2013.

T. Kamphuis, T. Meijerhof, T. Stegmann, J. Lederhofer, J. Wilschut et al., Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice, PLoS ONE, vol.7, p.36812, 2012.

T. Stegmann, T. Kamphuis, T. Meijerhof, E. Goud, A. De-haan et al., Lipopeptide-adjuvanted respiratory syncytial virus virosomes: a safe and immunogenic non-replicating vaccine formulation, Vaccine, vol.28, pp.5543-50, 2010.

J. Englund, W. P. Glezen, and P. A. Piedra, Maternal immunization against viral disease, Vaccine, vol.16, pp.1456-63, 1998.
DOI : 10.1016/s0264-410x(98)00108-x

H. Y. Chu and J. A. Englund, Maternal immunization, Clin Infect Dis, vol.59, pp.484-92, 2014.
DOI : 10.1002/bdra.23547

F. M. Munoz, P. A. Piedra, and W. P. Glezen, Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women, Vaccine, vol.21, pp.3465-3472, 2003.

Y. M. Kwon, H. S. Hwang, J. S. Lee, E. J. Ko, S. E. Yoo et al., Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease, Antiviral Res, vol.104, pp.1-6, 2014.

H. E. Nielsen, V. Siersma, S. Andersen, B. Gahrn-hansen, C. H. Mordhorst et al., Respiratory syncytial virus infection -risk factors for hospital admission: a case-control study, Acta Paediatr, vol.92, pp.1314-1335, 2003.

A. Eick, R. Karron, J. Shaw, B. Thumar, R. Reid et al., The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease, Pediatr Infect Dis J, vol.27, pp.207-219, 2008.

R. H. Parrott, H. W. Kim, J. O. Arrobio, D. S. Hodes, B. R. Murphy et al., Infection and disease with respect to age, immunologic status, race and sex, Am J Epidemiol, vol.98, pp.289-300, 1973.

L. R. Bulkow, R. J. Singleton, R. A. Karron, and L. H. Harrison, Risk factors for severe respiratory syncytial virus infection among Alaska native children, Pediatrics, vol.109, pp.210-216, 2002.
DOI : 10.1542/peds.109.2.210

L. G. Stensballe, H. Ravn, K. Kristensen, K. Agerskov, T. Meakins et al., Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze, J Allergy Clin Immunol, vol.123, pp.398-403, 2009.

J. J. Shinoff, K. L. O'brien, B. Thumar, J. B. Shaw, R. Reid et al., Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus, J Infect Dis, vol.198, pp.1007-1022, 2008.

P. Kaaijk, W. Luytjes, and N. Y. Rots, Vaccination against RSV: is maternal vaccination a good alternative to other approaches, Hum Vaccin Immunother, vol.9, pp.1263-1270, 2013.